An open-label, randomised, comparative, multicentre study of the immunogenicity and safety of ZOSTAVAX when administered by intramuscular route or subcutaneous route to subjects >=50 years of age.

Trial Profile

An open-label, randomised, comparative, multicentre study of the immunogenicity and safety of ZOSTAVAX when administered by intramuscular route or subcutaneous route to subjects >=50 years of age.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary) ; Varicella zoster virus vaccine live (Primary)
  • Indications Herpes zoster
  • Focus Pharmacodynamics
  • Sponsors Merck Sharp & Dohme; sanofi pasteur MSD
  • Most Recent Events

    • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Apr 2013 Planned End Date changed from 1 Apr 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 20 Sep 2012 Planned end date changed from 1 Jun 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top